BFRI BIOFRONTERA INC

Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025

Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025

Woburn, MA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc., (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and six months ended June 30, 2025 on Wednesday, August 13, 2025. The results will be released after the market close on Wednesday, August 13 and the company will host a conference call on Thursday, August 14 at 10:00am Eastern Time.

Conference Call and Webcast Information

Event:Biofrontera Inc. Second Quarter 2025 Financial Results and Business Update Conference Call
Date:Thursday, August 14, 2025
Time:10:00am ET
Conference Call:1-877-877-1275 (U.S.)

1-412-858-5202 (international)
Webcast:
  

About Biofrontera Inc.

Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the development and treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz ® with the RhodoLED ® lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit  and follow Biofrontera on  and .

Contacts:

Investor Relations

Andrew Barwicki

1-516-662-9461



EN
04/08/2025

Underlying

BFRIBIOFRONTERA INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BIOFRONTERA INC

 PRESS RELEASE
Free
BFRI BIOFRONTERA INC

Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics S...

Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities Phase 1 maximal-use pharmacokinetics (PK) study completed in support of planned U.S. label expansionData to complement previously announced positive Phase 3 efficacy results on extremities, neck and trunkSupplemental NDA submission for extremities, neck and trunk indication expected in Q3 2026 WOBURN, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the dev...

February 17, 2026 1 EN
 PRESS RELEASE
Free
BFRI BIOFRONTERA INC

Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug A...

Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma Prescription Drug User Fee Act (PDUFA) target action date set for September 28, 2026If approved, Ameluz® would be the first and only PDT photosensitizer indicated for the treatment of superficial Basal Cell Carcinoma (sBCC) in the USBCC is the most common skin cancer in the US with 3.6 million cases diagnosed annually1 WOBURN, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical compa...

February 11, 2026 1 EN
 PRESS RELEASE
Free
BFRI BIOFRONTERA INC

Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT...

Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint Study findings met its primary endpoint and showed highly statistically significant superiority for Ameluz® vs. vehicle gel (p

February 9, 2026 1 EN
 PRESS RELEASE
Free
BFRI BIOFRONTERA INC

Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Reve...

Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth Fourth quarter results represent highest quarterly revenue in Company’s historyQ4 year-over-year growth of 35% to 39% driven by sales execution of Ameluz®Full year 2025 revenues also expected to show double-digit growth of 11% to 13% WOBURN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a leader in photodynamic therapy (PDT) development and commercialization, to...

January 13, 2026 1 EN
 PRESS RELEASE
Free
BFRI BIOFRONTERA INC

Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Su...

Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones Database locks for studies on actinic keratosis (AK) and acne vulgaris achieved on January 5, 2026Data generated will support key regulatory milestones for Ameluz PDT in both indicationsAK and acne are the two most commonly diagnosed skin disorders in the US1 WOBURN, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy...

January 8, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch